Visual outcomes and cost-utility analyses of toric intraocular lens implantation in cataract patients over 80 with corneal astigmatism: a retrospective cohort study.

IF 1.9 4区医学 Q2 OPHTHALMOLOGY

Ophthalmic Research Pub Date : 2025-08-27 DOI:10.1159/000547708

Jiaqi Sun, Baojiang Li, Bijun Zhu, Yuyu Miao, Qian Sun, Huiyi Jin, Ying Zheng, Senlin Lin, Haidong Zou, Yingyan Ma

{"title":"Visual outcomes and cost-utility analyses of toric intraocular lens implantation in cataract patients over 80 with corneal astigmatism: a retrospective cohort study.","authors":"Jiaqi Sun, Baojiang Li, Bijun Zhu, Yuyu Miao, Qian Sun, Huiyi Jin, Ying Zheng, Senlin Lin, Haidong Zou, Yingyan Ma","doi":"10.1159/000547708","DOIUrl":null,"url":null,"abstract":"Introduction: This study aimed to assess visual and refractive outcomes and cost utility of toric intraocular lens (IOLs) implantation in cataract patients over 80 with corneal astigmatism.Methods: Patients >= 80 years with corneal astigmatism >= 1.50 diopters (D) who underwent cataract surgery with toric or monofocal IOLs were enrolled. Uncorrected distance visual acuity (UDVA) and residual refractive astigmatism at the 3-month postoperative follow-up were compared between the toric and non-toric groups. Cost data were gathered, long-term quality-adjusted life years (QALYs) were calculated, and the incremental cost-effectiveness ratio (ICER) was determined.Results: The study included 50 eyes from 50 patients, with 25 eyes receiving toric IOLs and the remaining 25 receiving non-toric IOLs. Three months after surgery, both the mean UDVA (P < 0.0001) and the mean residual refractive astigmatism (P < 0.0001) in the toric group significantly outperformed those in the non-toric group. An average of 4.04 ± 0.25 QALYs were obtained in the toric group through cataract surgery, while 3.78 ± 0.26 QALYs were obtained in the non-toric group. The median ICER stood at 11,222 CNY (1,753 USD) per QALY [95% CI: 5,840 ~ 25,295 CNY (913 ~ 3,952 USD) per QALY], which is lower than the threshold of cost-effectiveness in China (80,976 CNY (12,653 USD) per QALY).Conclusion: In cataract patients aged over 80 with corneal astigmatism and no complicating vision-threatening conditions, toric IOL implantation not only improved UDVA and reduced residual astigmatism but also emerged as a cost-effective intervention compared with non-toric IOL implantation.","PeriodicalId":19662,"journal":{"name":"Ophthalmic Research","volume":" ","pages":"1-16"},"PeriodicalIF":1.9000,"publicationDate":"2025-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000547708","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aimed to assess visual and refractive outcomes and cost utility of toric intraocular lens (IOLs) implantation in cataract patients over 80 with corneal astigmatism.

Methods: Patients >= 80 years with corneal astigmatism >= 1.50 diopters (D) who underwent cataract surgery with toric or monofocal IOLs were enrolled. Uncorrected distance visual acuity (UDVA) and residual refractive astigmatism at the 3-month postoperative follow-up were compared between the toric and non-toric groups. Cost data were gathered, long-term quality-adjusted life years (QALYs) were calculated, and the incremental cost-effectiveness ratio (ICER) was determined.

Results: The study included 50 eyes from 50 patients, with 25 eyes receiving toric IOLs and the remaining 25 receiving non-toric IOLs. Three months after surgery, both the mean UDVA (P < 0.0001) and the mean residual refractive astigmatism (P < 0.0001) in the toric group significantly outperformed those in the non-toric group. An average of 4.04 ± 0.25 QALYs were obtained in the toric group through cataract surgery, while 3.78 ± 0.26 QALYs were obtained in the non-toric group. The median ICER stood at 11,222 CNY (1,753 USD) per QALY [95% CI: 5,840 ~ 25,295 CNY (913 ~ 3,952 USD) per QALY], which is lower than the threshold of cost-effectiveness in China (80,976 CNY (12,653 USD) per QALY).

Conclusion: In cataract patients aged over 80 with corneal astigmatism and no complicating vision-threatening conditions, toric IOL implantation not only improved UDVA and reduced residual astigmatism but also emerged as a cost-effective intervention compared with non-toric IOL implantation.

查看原文本刊更多论文

80岁以上角膜散光白内障患者环形人工晶状体植入术的视力结果和成本-效用分析：一项回顾性队列研究。

本研究旨在评估80岁以上伴有角膜散光的白内障患者的视力和屈光效果以及人工晶状体植入术的成本效益。方法：选取>= 80岁、>= 1.50屈光度(D)行环形或单焦点人工晶状体白内障手术的患者。比较两组术后3个月随访时未矫正距离视力（UDVA）和残余屈光散光。收集成本数据，计算长期质量调整寿命年（QALYs），确定增量成本-效果比（ICER）。结果：本研究纳入50例患者的50只眼，其中25只眼接受环状体人工晶状体，其余25只眼接受非环状体人工晶状体。术后3个月，环面组平均UDVA （P < 0.0001）和平均残余屈光散光（P < 0.0001）均明显优于非环面组。白内障手术后，环面组的QALYs平均为4.04±0.25，非环面组的QALYs平均为3.78±0.26。ICER的中位数为11,222元人民币（1,753美元）/ QALY [95% CI: 5,840 ~ 25,295元人民币（913 ~ 3,952美元）/ QALY]，低于中国的成本效益阈值（80,976元人民币（12,653美元）/ QALY）。结论：对于80岁以上合并角膜散光且无并发症的白内障患者，环形人工晶状体植入术不仅改善了UDVA，减少了残余散光，而且与非环形人工晶状体植入术相比，是一种具有成本效益的干预措施。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic Research 医学-眼科学

CiteScore

3.80

自引率

4.80%

发文量

审稿时长

6-12 weeks

期刊介绍： ''Ophthalmic Research'' features original papers and reviews reporting on translational and clinical studies. Authors from throughout the world cover research topics on every field in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.